Loading…
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an at...
Saved in:
| Published in: | Journal for immunotherapy of cancer 2018-06, Vol.6 (1), p.46-17, Article 46 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383 |
| container_end_page | 17 |
| container_issue | 1 |
| container_start_page | 46 |
| container_title | Journal for immunotherapy of cancer |
| container_volume | 6 |
| creator | Gong, Jun Le, Thang Q Massarelli, Erminia Hendifar, Andrew E Tuli, Richard |
| description | Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibitors. Preclinical data support the rational combination of the 2 modalities and has paved way for the clinical development of the combination across a spectrum of cancers. In this review, we highlight the preclinical and clinical development of combined RT and PD-1/PD-L1 blockade to date. In addition to a comprehensive evaluation of available safety and efficacy data, we discuss important points of consideration in clinical trial design for this promising combination. |
| doi_str_mv | 10.1186/s40425-018-0361-7 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_16c95f762a164a7697fa1d2032c8938e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546888545</galeid><doaj_id>oai_doaj_org_article_16c95f762a164a7697fa1d2032c8938e</doaj_id><sourcerecordid>A546888545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383</originalsourceid><addsrcrecordid>eNptkl1rFDEUhgdRbKn9Ad7IgCC9mTbJ5Gu8EEr9KiwootfhbJLZzZpJ1mRmof_eTLfWXZHAJCTP-07OyVtVLzG6xFjyq0wRJaxBWDao5bgRT6pTghhuMCX86cH6pDrPeYMQwqhtpZTPqxPSSc5xJ04r9w2Mg9HFUI9rm2B7V0Mw9df3Db4qnwWulz7qn2Ds2xmotXfBafC1sTvr43awYaxjX0S13UW_c2FV1mNBgrap1nFYunDv_6J61oPP9vxhPqt-fPzw_eZzs_jy6fbmetFozsTYdJrqjlJYGloqEABAOiPL7ZeIcM0Yx9Yy2RPgvbYYIw2SCGp6wKTtdSvbs-p272sibNQ2uQHSnYrg1P1GTCsFqVzQW4W57lgvOAHMKQjeiWJjCGqJll0rbfF6t_faTsvBGl2KTeCPTI9PglurVdwp1klBJS8GFw8GKf6abB7V4LK23kOwccqqlIioFILM6Ot_0E2cUiitUuVUok60jPylVlAKcKGP5b96NlXXjPLyvIyyQl3-hyrD2MHpGGzvyv6R4M2BYG3Bj-sc_TQ_XD4G8R7UKeacbP_YDIzUnEu1z6UquVRzLpUomleHXXxU_Elh-xuZV9qS</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638097352</pqid></control><display><type>article</type><title>Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination</title><source>BMJ Open Access Journals</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gong, Jun ; Le, Thang Q ; Massarelli, Erminia ; Hendifar, Andrew E ; Tuli, Richard</creator><creatorcontrib>Gong, Jun ; Le, Thang Q ; Massarelli, Erminia ; Hendifar, Andrew E ; Tuli, Richard</creatorcontrib><description>Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibitors. Preclinical data support the rational combination of the 2 modalities and has paved way for the clinical development of the combination across a spectrum of cancers. In this review, we highlight the preclinical and clinical development of combined RT and PD-1/PD-L1 blockade to date. In addition to a comprehensive evaluation of available safety and efficacy data, we discuss important points of consideration in clinical trial design for this promising combination.</description><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1186/s40425-018-0361-7</identifier><identifier>PMID: 29866197</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Antigens ; Antitumor ; Apoptosis ; Cancer ; Care and treatment ; Clinical trials ; Combined Modality Therapy - methods ; Cytotoxicity ; Disease Models, Animal ; FDA approval ; Health aspects ; Humans ; Immunization ; Immunotherapy ; Ionizing radiation ; Ligands ; Melanoma ; Metastasis ; Mice ; Multiple myeloma ; Neoplasms - drug therapy ; Neoplasms - radiotherapy ; PD-1 ; PD-L1 ; Preclinical ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Radiation therapy ; Radiotherapy ; Radiotherapy - methods ; Review ; T cells ; Tumors ; Vaccines</subject><ispartof>Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.46-17, Article 46</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383</citedby><cites>FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2638097352/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2638097352?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25752,27921,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29866197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gong, Jun</creatorcontrib><creatorcontrib>Le, Thang Q</creatorcontrib><creatorcontrib>Massarelli, Erminia</creatorcontrib><creatorcontrib>Hendifar, Andrew E</creatorcontrib><creatorcontrib>Tuli, Richard</creatorcontrib><title>Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><description>Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibitors. Preclinical data support the rational combination of the 2 modalities and has paved way for the clinical development of the combination across a spectrum of cancers. In this review, we highlight the preclinical and clinical development of combined RT and PD-1/PD-L1 blockade to date. In addition to a comprehensive evaluation of available safety and efficacy data, we discuss important points of consideration in clinical trial design for this promising combination.</description><subject>Animals</subject><subject>Antigens</subject><subject>Antitumor</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy - methods</subject><subject>Cytotoxicity</subject><subject>Disease Models, Animal</subject><subject>FDA approval</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunotherapy</subject><subject>Ionizing radiation</subject><subject>Ligands</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Multiple myeloma</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - radiotherapy</subject><subject>PD-1</subject><subject>PD-L1</subject><subject>Preclinical</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Radiotherapy - methods</subject><subject>Review</subject><subject>T cells</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1rFDEUhgdRbKn9Ad7IgCC9mTbJ5Gu8EEr9KiwootfhbJLZzZpJ1mRmof_eTLfWXZHAJCTP-07OyVtVLzG6xFjyq0wRJaxBWDao5bgRT6pTghhuMCX86cH6pDrPeYMQwqhtpZTPqxPSSc5xJ04r9w2Mg9HFUI9rm2B7V0Mw9df3Db4qnwWulz7qn2Ds2xmotXfBafC1sTvr43awYaxjX0S13UW_c2FV1mNBgrap1nFYunDv_6J61oPP9vxhPqt-fPzw_eZzs_jy6fbmetFozsTYdJrqjlJYGloqEABAOiPL7ZeIcM0Yx9Yy2RPgvbYYIw2SCGp6wKTtdSvbs-p272sibNQ2uQHSnYrg1P1GTCsFqVzQW4W57lgvOAHMKQjeiWJjCGqJll0rbfF6t_faTsvBGl2KTeCPTI9PglurVdwp1klBJS8GFw8GKf6abB7V4LK23kOwccqqlIioFILM6Ot_0E2cUiitUuVUok60jPylVlAKcKGP5b96NlXXjPLyvIyyQl3-hyrD2MHpGGzvyv6R4M2BYG3Bj-sc_TQ_XD4G8R7UKeacbP_YDIzUnEu1z6UquVRzLpUomleHXXxU_Elh-xuZV9qS</recordid><startdate>20180604</startdate><enddate>20180604</enddate><creator>Gong, Jun</creator><creator>Le, Thang Q</creator><creator>Massarelli, Erminia</creator><creator>Hendifar, Andrew E</creator><creator>Tuli, Richard</creator><general>BioMed Central Ltd</general><general>BMJ Publishing Group LTD</general><general>BioMed Central</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180604</creationdate><title>Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination</title><author>Gong, Jun ; Le, Thang Q ; Massarelli, Erminia ; Hendifar, Andrew E ; Tuli, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Antitumor</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy - methods</topic><topic>Cytotoxicity</topic><topic>Disease Models, Animal</topic><topic>FDA approval</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunotherapy</topic><topic>Ionizing radiation</topic><topic>Ligands</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Multiple myeloma</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - radiotherapy</topic><topic>PD-1</topic><topic>PD-L1</topic><topic>Preclinical</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Radiotherapy - methods</topic><topic>Review</topic><topic>T cells</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gong, Jun</creatorcontrib><creatorcontrib>Le, Thang Q</creatorcontrib><creatorcontrib>Massarelli, Erminia</creatorcontrib><creatorcontrib>Hendifar, Andrew E</creatorcontrib><creatorcontrib>Tuli, Richard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gong, Jun</au><au>Le, Thang Q</au><au>Massarelli, Erminia</au><au>Hendifar, Andrew E</au><au>Tuli, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><addtitle>J Immunother Cancer</addtitle><date>2018-06-04</date><risdate>2018</risdate><volume>6</volume><issue>1</issue><spage>46</spage><epage>17</epage><pages>46-17</pages><artnum>46</artnum><issn>2051-1426</issn><eissn>2051-1426</eissn><abstract>Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibitors. Preclinical data support the rational combination of the 2 modalities and has paved way for the clinical development of the combination across a spectrum of cancers. In this review, we highlight the preclinical and clinical development of combined RT and PD-1/PD-L1 blockade to date. In addition to a comprehensive evaluation of available safety and efficacy data, we discuss important points of consideration in clinical trial design for this promising combination.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29866197</pmid><doi>10.1186/s40425-018-0361-7</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2051-1426 |
| ispartof | Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.46-17, Article 46 |
| issn | 2051-1426 2051-1426 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_16c95f762a164a7697fa1d2032c8938e |
| source | BMJ Open Access Journals; Publicly Available Content Database; PubMed Central |
| subjects | Animals Antigens Antitumor Apoptosis Cancer Care and treatment Clinical trials Combined Modality Therapy - methods Cytotoxicity Disease Models, Animal FDA approval Health aspects Humans Immunization Immunotherapy Ionizing radiation Ligands Melanoma Metastasis Mice Multiple myeloma Neoplasms - drug therapy Neoplasms - radiotherapy PD-1 PD-L1 Preclinical Programmed Cell Death 1 Receptor - antagonists & inhibitors Radiation therapy Radiotherapy Radiotherapy - methods Review T cells Tumors Vaccines |
| title | Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20therapy%20and%20PD-1/PD-L1%20blockade:%20the%20clinical%20development%20of%20an%20evolving%20anticancer%20combination&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Gong,%20Jun&rft.date=2018-06-04&rft.volume=6&rft.issue=1&rft.spage=46&rft.epage=17&rft.pages=46-17&rft.artnum=46&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1186/s40425-018-0361-7&rft_dat=%3Cgale_doaj_%3EA546888545%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c657t-9c4c944abd42057aaa29d8000b026c5561ee58f2a6fce110ca8274dfa123fc383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2638097352&rft_id=info:pmid/29866197&rft_galeid=A546888545&rfr_iscdi=true |